EP Patent

EP0531874A1 — Imidazopyridine derivatives and process for preparation thereof

Assigned to Tanabe Pharma Corp · Expires 1993-03-17 · 33y expired

What this patent protects

An imidazopyridine derivative of the formula [I]: wherein R¹ is hydrogen or lower alkyl, R² is hydrogen, lower alkylsulfonyl or a group of the formula: (Z is oxygen atom or two hydrogen, R⁰ is substituted or unsubstituted lower alkyl, lower alkoxy, 5- or 6-membe…

USPTO Abstract

An imidazopyridine derivative of the formula [I]: wherein R¹ is hydrogen or lower alkyl, R² is hydrogen, lower alkylsulfonyl or a group of the formula: (Z is oxygen atom or two hydrogen, R⁰ is substituted or unsubstituted lower alkyl, lower alkoxy, 5- or 6-membered heteromonocyclic, substituted or unsubstituted phenyl, hydrogen, substituted or unsubstitued amino or lower alkenyl), R³ is carboxyl or lower alkoxycarbonyl and Ring A is substituted or unsubstituted phenyl, and pharmaceutically acceptable salt thereof, and processes for preparation thereof, said imidazopyridine derivatives have excellent angiotensin II antagonistic activities and are useful in prophylaxis and treatment of hypertension.

Drugs covered by this patent

Patent Metadata

Patent number
EP0531874A1
Jurisdiction
EP
Classification
Expires
1993-03-17
Drug substance claim
No
Drug product claim
No
Assignee
Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.